GLP-1 receptor agonists and SGLT2 inhibitors protect the heart and kidneys through complementary mechanisms, and combining them may offer greater cardiorenal protection than either class alone.
Complementary mechanismsGLP-1 drugs reduce atherosclerotic events while SGLT2 inhibitors reduce heart failure and kidney disease — combining both may cover the full spectrum of cardiorenal risk
What the researchers found
GLP-1RAs primarily reduce atherosclerotic CV events (especially stroke) and renal outcomes, while SGLT2is reduce heart failure hospitalization and kidney disease progression. Post-hoc subgroup analyses suggest a combined GLP-1RA/SGLT2i therapy provides greater cardiorenal protection than monotherapy. The FLOW trial established semaglutide's renal protection. The PRECIDENTD trial will prospectively compare combination vs monotherapy.
Why it matters
Cardiovascular and kidney disease are the leading causes of death in type 2 diabetes. Having two drug classes that protect these organs through different mechanisms — and evidence that combining them works better — could fundamentally change how high-risk diabetes patients are managed.
The numbers in context
Both drug classes improve glucose, weight, and blood pressure while reducing cardiovascular and renal events.
How the study worked
Comprehensive narrative review examining published RCTs, cardiovascular outcome trials (CVOTs), and observational studies on GLP-1RAs and SGLT2is. Analyzes mechanistic differences, clinical trial data for individual and combined therapy, and real-world evidence.
Who was studied
Type 2 diabetes patients at high cardiovascular risk
What this study cannot tell us
Review article with no original data. Evidence for combination superiority comes mainly from post-hoc subgroup analyses, not dedicated prospective trials (PRECIDENTD is still ongoing). High cost of combination therapy limits accessibility. Both drug classes remain underused even as monotherapy.
How to read the evidence
Rated strong: comprehensive review synthesizing multiple large RCTs and CVOTs. Evidence for individual drug classes is robust; evidence for combination superiority is currently limited to post-hoc analyses pending the PRECIDENTD trial.
When this study was published
Published in 2024. Includes the most recent trial data including the FLOW trial for semaglutide's renal protection.
The bigger picture
This represents a shift toward multi-target cardiorenal protection in diabetes — using peptide-based drugs alongside complementary medications to cover different risk pathways. The challenge is translating this into practice given costs and global underuse of both drug classes.
Questions still open
- Will the PRECIDENTD trial confirm that GLP-1RA/SGLT2i combination is superior to either monotherapy for cardiorenal outcomes?
- How should clinicians prioritize which drug class to start first in high-risk patients?
- Could triple combinations (GLP-1RA + SGLT2i + dual GIP/GLP-1 agonist) provide even greater protection?
Common questions
Should diabetes patients take both GLP-1 drugs and SGLT2 inhibitors?
How do GLP-1 drugs and SGLT2 inhibitors differ in protecting the heart?
Read the original research
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.
Drugs, 84(11), 1347-1364
Citation
Scheen, André J. (2024). GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.. Drugs, 84(11), 1347-1364. https://doi.org/10.1007/s40265-024-02090-9